Oxygen-Deficient Molybdenum Oxide Nanosensitizers for Ultrasound-Enhanced Cancer Metalloimmunotherapy

Oxygen-deficient molybdenum oxide (MoOX) nanomaterials are prepared as novel nanosensitizers and TME-stimulants for ultrasound (US)-enhanced cancer metalloimmunotherapy. After PEGylation, MoOX-PEG exhibits efficient capability for US-triggered reactive oxygen species (ROS) generation and glutathione (GSH) depletion. Under US irradiation, MoOX-PEG generates a massive amount of ROS to induce cancer cell damage and immunogenic cell death (ICD), which can effectively suppress tumor growth. More importantly, MoOX-PEG itself further stimulates the maturation of dendritic cells (DCs) and triggeres the activation of the cGAS-STING pathway to enhance the immunological effect. Due to the robust ICD induced by SDT and efficient DC maturation stimulated by MoOX-PEG, the combination treatment of MoOX-triggered SDT and aCTLA-4 further amplifies antitumor therapy, inhibits cancer metastases, and elicits robust immune responses to effectively defeat abscopal tumors.

Automated summary

This article introduces the use of oxygen-deficient molybdenum oxide (MoOX) nanomaterials for ultrasound-enhanced cancer metalloimmunotherapy. After PEGylation, MoOX-PEG exhibits efficient capability for ultrasound-triggered reactive oxygen species (ROS) generation and glutathione (GSH) depletion. Under ultrasound irradiation, MoOX-PEG generates a massive amount of ROS to induce cancer cell damage and immunogenic cell death (ICD), effectively suppressing tumor growth. Furthermore, MoOX-PEG stimulates the maturation of dendritic cells (DCs) and activates the cGAS-STING pathway, enhancing the immunological effect.